The anticancer effects of Src kinase inhibitors are controversial. This study found an association between alterations in the TP53 gene and the synergy score for combination treatment with doxorubicin and an Src kinase inhibitor using human osteosarcoma cell lines (MG63 and U2OS) and human colon cancer cell line. Doxorubicin was found to activate signal transducer and activator of transcription 3 via Src kinase in cancer cells harboring alterations in TP53. A drug combination study using patient-derived cells confirmed that an Src kinase inhibitor synergizes with doxorubicin in cancer cells harboring alterations in TP53, while antagonizing its effect in cancer cells expressing wild-type TP53. Our findings suggest that genetic alterations in TP53 are a critical factor in determining the use of a combination treatment of doxorubicin and Src inhibitors.
Introduction
Doxorubicin (DOX) is a highly potent antitumor therapeutic agent widely used in the clinic. However, one of the main reasons for the problems encountered with its use in the clinic, and for its ultimate failure, is that cancer cells become resistant to DOX. Therefore, an understanding of the mechanisms underlying DOX resistance in various cancers is urgently needed. 1, 2 Src kinase, also known as Src proto-oncogene, plays a key role in the regulation of diverse cellular functions, including cell proliferation, differentiation, adhesion, and motility in both normal and cancer cells. Src kinase is overexpressed and abnormally activated in various human cancer cells and has been strongly implicated in tumorigenesis and metastatic progression. Current studies have demonstrated that increased Src activity correlates with disease progression and a poor clinical prognosis. [3] [4] [5] [6] Therefore, it would be expected that Src inhibitors could overcome the chemoresistance of common antitumor drugs.
In various clinical trials, Src inhibitors such as bosutinib, saracatinib, and dasatinib have been used either as single agents or in combination with chemotherapy. A clinical trial of bosutinib in chronic myeloid leukemia reported successful data. Two Phase 2 clinical trials using saracatinib failed to meet their primary endpoint in colon cancer and small-cell lung cancer patients. In another clinical trial using dasatinib for the treatment of breast cancer, only one patient exhibited a clinical benefit, 7 but unfortunately, the study failed to find a gene signature that defined tumor sensitivity to dasatinib. Combination therapy using Src kinase inhibitors and other agents have also reportedly shown poor outcomes. A combination of dasatinib and the receptor tyrosine kinase inhibitor erlotinib, 8 a combination of bosutinib and the aromatase inhibitor letrozole, 9 and a combination of dasatinib and docetaxel 10 were all reported to be unsuccessful.
During tumor progression, genetic heterogeneity occurs by the evolution of a variety of sub-clones. Within tumors, cellular heterogeneity is a major potential factor that can weaken the success of combination therapies. 11, 12 In this study, we aimed to find a key mutation that determines Src kinase sensitivity. This study characterizes the gene alterations that are associated with the synergistic effect of combination therapy with DOX and Src kinase. With our CancerSCAN V2 panel data, we have found that 380 cancer-related genes, including TP53, in these 14 cell lines. 13 We have performed that cancers with TP53 mutations are sensitive to a combination therapy of DOX and an Src kinase inhibitor. In addition, we evaluated the TP53-dependent mechanism for Src kinase that affects the use of Src kinase inhibitors. Finally, we demonstrate for the first time that TP53 is an important signature gene that defines tumors that are sensitive to combination therapy.
Materials and methods

Chemicals
DOX, SU6656 were purchased from Sigma-Aldrich (St. Louis, MO, USA) and AZD0530 were from Selleck Chemicals (Houston, TX, USA).
Cell culture conditions
A549, MCF7, MG63, and Huh7 cells were cultured in Dulbecco's modified Eagle's medium (DMEM), and U2OS, HepG2, and SaOS2 cells were cultured in Modified Eagle's medium (MEM). Prostate cancer cell lines (LNCaP, PC3, and DU145), HCT116, and MDA-MB468 cells were grown in RPMI1640 (HyClone Laboratories, Inc, Logan, UT, USA) with 10% fetal bovine serum (FBS) and 1% antibiotic-antimycotic solution. 143B cells were cultured in Eagle's minimal essential medium (EMEM; Bio Whittaker, Lonza, Walkersville, MD) with 10% FBS and 1% antibioticantimycotic solution. All patient tissue samples were approved by the Institutional Review Board (IRB) in Samsung Medical center in accordance with the regulation of involved institutions and provided an informed consent from all patients. Patient tissues were washed with phosphate-buffered saline (PBS) and minced into small pieces of 2-4 mm using a scalped blade. The minced tissues were transferred into conical tube and dissociated at 37°C for 3 h with collagenase. Patientderived cells (PDCs) were cultured in RPMI1640 with 10% FBS and 1% antibiotic-antimycotic solution.
Determination of TP53 status
The TP53 status of the cell lines was based on the International Agency for Research on Cancer (IARC) TP53 database as described in previous studies. 13, 14 The TP53 transcription status of the samples were determined by CancerSCAN, an internal development kit for sequencing of target gene that uses an Illumina HiSeq 2000 (Illumina Inc, San Diego, CA, USA). These were further confirmed by real-time polymerase chain reaction (RT-PCR) and Sanger sequencing, respectively, and the p53 mutation status of cell lines were shown in detail as supplementary table in the previous study. 15 To amplify and sequence the p53 transcript, PCR was performed using the following primers: p53-specific primers, forward 5#-ctgggctccggggacacttt-3# and reverse 5#-cgcacacctattgcaagc-3#.
Cell viability assay
Cell viability assay was measured using a previously described procedure. 15 Cell viability was determined by dissolve the formazan crystals using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay according to the manufacturer's protocol (SigmaAldrich), and the absorbance was read at 570 nm.
Evaluation of the drug combination effect
The combination effect of DOX/Src inhibitors was measured using the Bliss independence 16 and Loewe additivity model, 17, 18 as described previously.
15
Animal experiment HCT116-/-cells (5 3 10 6 cells) were injected subcutaneously into 6-week-old female BALB/c-nude mice (Orient Bio Inc, Seoul, Korea). At an approximate tumor volume of 50 mm 3 , the mice were injected intraperitoneally with DOX (2.5 mg/kg) every 3 days. The tumors were excised 2 weeks after DOX treatment and performed to immunohistochemistry analysis.
Immunohistochemistry analysis
Tumor tissues taken from mice were fixed in 4% paraformaldehyde and then paraffin embedded, sections were deparaffinized in xylene. The samples were subjected to heat-induced epitope retrieval (HIER) with citrate buffer (pH 6.0; Dako, Carpinteria, CA, USA) for 3 min at 121°C. 19 Subsequently, endogenous peroxidase was blocked with 3% hydrogen peroxide in PBS for 10 min at room temperature. Sections were washed in PBS, and treated with normal goat for 20 min at room temperature to block non-specific binding, 20 and incubated with an anti-phospho (Y416)-Src antibody (Novus Biologicals, Littleton, CO, USA) for 16 h at 4°C. The sections were incubated for 30 min at room temperature with a horseradish peroxidase (HRP)-conjugated secondary antibody against rabbit IgG. Finally, the sections were lightly counterstained with Mayer's hematoxylin for 1 min.
Immunofluorescent staining
The effects of DOX on Src activity in HCT116+/+ and HCT116-/-cells were measured according to the previously described method with minor modification. 21 Cells were cultured on glass coverslips (Fisher Scientific, Pittsburgh, PA, USA) and treated with 0.5 mM DOX for 16 h. Following wash with PBS, the cells were fixed in 3.7% paraformaldehyde and permeabilized with 0.5% Triton X-100 in PBS. Subsequently, coverslips were incubated for 1 h in 1% bovine serum albumin (BSA) and incubated with a rabbit anti-phospho-Src (Y416) antibody (Cell Signaling Technology, Danvers, MA, USA), followed by incubation with contained a fluorescent dye-conjugated secondary antibody (goat anti-rabbit Alexa 488, Invitrogen), for 2 h. The slides were mounted with Vectashield mounting medium containing DAPI (4',6-Diamidino-2-Phenylindole; Vector Laboratories, Burlingame, CA, USA) and visualized using a Zeiss LSM 780 laser scanning confocal microscope (Carl Zeiss Inc, Go¨ttingen, Germany).
Plasmid, siRNA transfection pcDNA-p53 was cloned via the insertion of the p53 gene coding sequence (NM_000546) into pcDNA3.1. pcDNA-CA-Src (constitutive active form, Y530) was cloned using pcDNA3-MTS-CA-c-Src-FLAG that was provided by Dr Yoshimi Homma (Addgene plasmid #44654). The amplified coding sequences of p53 and CA-Src (Supplementary Table2) were digested with HindIII (underlined) and EcoRI (underlined in italic) and then ligated into HindIII and EcoRI digested pcDNA3.1, respectively. The sequence of plasmids was confirmed by Sanger sequencing. Plasmids were transfected using Lipofectamine 
Immunoblot analysis
The cells (1.5 3 10 5 cells) were plated in six-well plates. After drug treatment, the cells were washed with PBS and lysed in radioimmunoprecipitation assay (RIPA) buffer containing 150-mM NaCl, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 50-mM Tris-HCl (pH 8.0) supplemented with protease inhibitor cocktail (ThermoScientific, Piscataway, NJ, USA). 
Statistical analysis
Statistical analysis of the data was signified as the mean 6 SD. Comparisons between two groups were performed using the non-parametric Mann-Whitney test or two tailed t-test using GraphPad Prism 5 (GraphPad Software, Inc, La Jolla, CA, USA).
Results
Src kinase is a well-known survival factor that is found in various types of cancer cells. Our hypothesis was that a synergistic anticancer effect should occur when using a combination of DOX and an Src inhibitor. To address this hypothesis, we first analyzed the effect on cell viability in 14 different cancer cell lines treated with DOX and a Src inhibitor using the bliss synergy score (Figure 1(a) ). Unexpectedly, we found that this combination showed a synergistic effect in some cancer cell lines (HCT116-/-, MDA-MB468, DU145, MG63, 143B, Huh7, SaOS2, PC3, LNCaP, and MCF7) but an antagonistic effect in other cell lines (HCT116+/+, A549, U2OS, and HepG2). In a previous study, 15 we verified that 380 cancer-related genes (CancerSCAN V2) in a human colon cancer cell line (HCT116), a human hepatoma cell lines (HepG2 and Huh7), a human non-small-cell lung cancer cell line (A549), human osteosarcoma cell lines (MG63, SaOS2, 143B and U2OS), human prostate cancer cell lines (PC3, LNCaP and DU145) and human breast cancer cell line (MCF7 and MDA-MB468). The results for the Figure 1 . Continued mutational status of p53 in the cancer cell lines were also showed in the supplementary table of a previous study. 15 We found that an alteration in TP53 was significantly associated with a high synergy score. In other words, the data in Figure 1(a) show that the eight cancer cells with an alteration in TP53 had a synergistic effect of DOX plus the Src inhibitor, whereas four of the six cancer cells with wild-type TP53 showed an antagonistic effect. We also found the relationship between an alteration in TP53 and Src activity by using the open-source data generated by The Cancer Genome Atlas (TCGA) research network. Among 33 data sets that contained both the phosphoprotein level (measured by Reverse Phase Protein Array, RPPA) and genomic data, five of these data sets demonstrated a significant increase in phosphorylated Src in the TP53-altered group (p \ 0.001; Figure 1(b) ). Based on these results, we evaluated the activation of Src by DOX in TP53-altered cells. As shown in Figure 1(c) , the expression levels of Src increased markedly following DOX treatment in the TP53-altered HCT116 (-/-) tumor model. To test whether DOX could induce Src activity depending on the p53 status, the phosphorylation of Src was evaluated at the protein level. TP53-altered HCT116 (-/-) and TP53 wild-type HCT116 (+/+) cells were treated with DOX for 16 h, and the expression of pSrc was quantified by immunostaining. pSrc levels were found to be increased following treatment with 0.5-mM DOX in both cells (Figure 1(d) ). DOX-induced Src activation was further evaluated in TP53 wild-type cells (HCT116+/+, U2OS) and TP53-altered cells (HCT116-/-), as well as TP53-null cells (MG63) by Western blotting. A higher level of Src phosphorylation was detected in TP53-altered cells and TP53-null cells, compared with wild-type TP53 cells (Figure 1(e) ).
Bliss analysis also showed the synergy of DOX/ SU6656 treatment in the TP53-altered cells, but there was antagonism in the wild-type TP53 cells ( Figure  1(f) ). In addition, another Src inhibitor AZD0530 also showed a significant synergy score dependent on TP53 status (Figure 1(g) ).
TP53 gain and loss of function study
When p53 was silenced in TP53 wild-type cells (U2OS), the synergy score was increased compared with the control cells (Figure 1(h) ). An isobologram showed that AZD0530 possessed an antagonistic effect at a low dose of DOX. However, when p53 was silenced, AZD0530 had a synergic effect at all doses of DOX tested ( Figure  1(h) lower panel) . In contrast, when p53 was ectopically expressed in TP53-altered MG63 cells, the synergy score was decreased compared with the control (Figure  1(i) ). Therefore, alterations in TP53 are a key mechanism for the synergistic effect of both agents.
A gain and loss of function study for Src kinase identifies a novel Src kinase/TP53 pathway
To understand the role of Src kinase, we introduced a constitutively active Src mutant (c-Src Y530 mutant) into HCT116 cells. The activation of JNK and STAT3, which respectively mediate cell death and survival, were then evaluated using Western blot. The activated Src mutant induced the activation of both JNK and STAT3, independently of p53 expression. Phosphorylation of JNK was increased in wild-type TP53 cells compared with TP53-altered cells. However, STAT3 activation occurred in a converse manner (Figure 2(a)) . Surprisingly, we found activated Src can also induce p53 phosphorylation, which promotes apoptosis with DOX treatment (Figure 2(b) ). Using an Src inhibitor, SU6656, we further confirmed that inhibition of Src led to the inactivation of p53 and STAT3. Interestingly, DOX induced the activation of STAT3 in TP53-altered MG63 cells, but there was an inactivation of STAT3 in U2OS cells expressing wild-type TP53. P53 is known to negatively modulate STAT3 phosphorylation and DNA binding activity in cancer cells. 22 It appears that although STAT3 can be activated in a TP53 status-independent manner, STAT3 activation was repressed by the predominant activity of p53 in U2OS cells expressing wild-type TP53 (Figure 2(a) and  (d) ). As shown in Figure 2(c) , the protein levels of p-JNK increased in response to DOX exposure. To confirm activation of JNK which mediated cell death result, apoptosis-related proteins by DOX were observed by immunoblotting. The levels of active form of apoptotic marker, cleaved poly [ADP-ribose] polymerase (PARP) increased in response to treatment of DOX alone in U2OS cells, and the combination of DOX and SU6656 decreased the active form of PARP (Figure 2(e) ), which could not be confirmed in p53-altered MG63 cells. Next, we asked whether STAT3 was related to cell viability by DOX, depending on the state of TP53. Cells were transfected with an siRNAtargeting STAT3 to decrease its levels and were then treated with DOX at concentrations ranging from 0.25 to 4 mM for 24 h (Figure 2(f) ). An MTT assay showed the effect of STAT3 expression levels on the growth of cells with an alteration in TP53 (HCT116-/-and MG63 cells). Our data suggest that DOX induces cell death in wild-type TP53 cells but increases resistance via STAT3 in cells with an alteration in TP53. Based on these data, we propose a model for the TP53-dependent biphasic role of Src (Figure 2(g)) Further testing of TP53-associated synergism with patient-derived cancer cells (PDCs)
We found that Src inhibitors enhanced the anticancer effect of DOX in cancer cells with an alteration in TP53-but repressed the effect of DOX in cancer cells expressing wild-type TP53. Based on this result, we established a new treatment strategy based on TP53 status, and conducted a synergy test with PDCs to confirm the possibility of clinical application. First of all, CancerSCAN or Sanger sequencing was performed on patient-derived tissues to determine their TP53 status. TP53 wild-type and TP53-altered PDCs were defined as the control and experimental groups, respectively. There were a total of 26 PDCs that satisfied the conditions described in section ''Materials and methods,'' with 16 in the control group and 10 in the experimental group. To test the effect of combination treatment with DOX/AZD0530, the PDCs were treated with a combination of different doses of DOX (0, 0.25, 1, 2, and 4 mM) and AZD0530 (0, 0.25, 0.5, 1, 2, and 4 mM). Following the combination treatment, cell viability was measured to compare growth inhibition between control and experimental groups using the Loewe synergy scores (Supplementary Figure  1, Supplementary Table1) .
The average synergy scores of the control group and experimental groups were 1.138 6 0.620 (DOX/ AZD0530) and 2.882 6 0.736 (DOX/AZD0530), respectively. In contrast to the control group, the antagonistic effect of the combination was observed in experimental group. The difference between two groups was evaluated using a non-parametric method and was found to be highly significant (***p \ 0.001; Figure 3) . Especially, gastric cancer (#31, #34, #36) showed significantly higher synergy scores (Supplementary Table 1 ). Based on the PDCs study, we conclude that the combination of DOX/AZD0530 has a synergistic effect in cancers with alterations in TP53. In addition, TP53 status is a critical factor in predicting the response to DOX/AZD0530 combination therapy.
Discussion
The mechanism of resistance to DOX has been widely studied and is thought to occur through an inherent resistance pathway. 23 Several cell-signaling molecules have been found to be altered in DOX-resistant cells, such as p-glycoprotein, MAPK, and cyclin. Naturally DOX-resistant K562 cells were found to have a reduced resistance to DOX when a p-glycoprotein inhibitor was administered. 24 MAPK inhibition had a similar effect because MAPK is known to be downstream of p-glycoprotein. 25 Cyclin proteins stimulate cell growth, so DOX antagonizes the effect of cyclin due to its growth arrest function. 26 However, signal transduction-related proteins are incredibly complicated, and it is difficult to justify a single mechanism of resistance. 27 A role for Src in the mechanism of resistance to DOX has not been previously described; therefore, our study is the first to find that Src kinase is associated with DOX resistance in cancer cells. Src has been implicated in the transcriptional regulation of other transcription factors, which are important components of many signaling pathways. For example, Src has been shown to be associated with myogenin, MEF-2, transcriptional enhancer factor (TEF), NF-kappaB, AP-1, JNK, STAT, p53, and E2F1, which are known to be involved in many physiological processes. 28 STAT3, a transcription factor with vital roles in tumors, can also be activated by Src. 29 Here, we showed that DOX activates Src kinase and its downstream STAT3, which is closely linked to cell proliferation and survival pathways. Therefore, we think that DOX-induced Src kinase activity is a crucial event in DOX resistance. Indeed, inhibition of Src kinase successfully synergized the cytotoxic effect of DOX in a group of cancers that had alterations in TP53. However, in cancer cells expressing wild-type TP53, Src kinase inhibition did not show effective synergism with DOX. Numerous other studies have shown diverse outcomes with respect to the anticancer effect of Src kinase inhibitors, but the reason for this has not yet been elucidated. The mechanism we investigated here focused on the effect of the Src/p53/STAT3 pathway and its regulation of DOX resistance. This study has identified for the first time a significant subgroup of cancers (i.e. a TP53 mutant subgroup) that were sensitive to the Src kinase inhibitor.
We also found that Src kinase activates p53, which explains why Src kinase inhibitors did not effectively synergize with the cytotoxic effect of DOX in TP53 wild-type cancers.
Other studies have shown that Src kinase can induce the JNK/p53 pathway, with the JNK activation establishing a positive feedback loop with p53. 30 From the data shown in Figures 2(c) and (d), we noticed that Src kinase inhibition decreased p53-induced apoptosis by inhibiting the phosphorylation of p53, which was unexpected. The p53 pathway is likely to be the predominant signaling pathway in TP53 wild-type cancers; therefore, the Src kinase-induced survival signal was not able to inhibit the cytotoxic effect of DOX. Instead, we hypothesize that this pathway supports the anticancer effect by activating the p53-induced apoptosis pathway.
In this PDCs study, gastric cancer showed significantly higher synergy scores, and analysis with TCGA indicated that there are 47% mutations in TP53. We confirmed that Src inhibitors might be safe for use in cancer patients harboring an alteration in TP53, and tumors with high TP53 mutations are expected to be helpful in therapy. In contrast, it is obvious that Src inhibitors should be avoided in cancer patients Figure 3 . Synergistic effect of TP53. The significance of the difference between the TP53 wild-type and altered groups was compared using the Mann-Whitney test. Significant differences are marked by asterisks (***p\0.001).
harboring wild-type TP53 because the chemotherapeutic effect of DOX is significantly reduced by the Src inhibitor.
This study has a limitation in not evaluating side effects, such as cytotoxicity, in human body. Because normal cells have an intact TP53 gene in most patients, combination therapy may not critically affect normal tissues that are vulnerable to chemotherapeutic agents.
Cancers have complex genetic mutations, and single tumors have genetic heterogeneity. Therefore, our simple therapeutic strategy based on TP53 status cannot be applied to all clinical cases. Nevertheless, this study suggests that TP53 status can predict if an Src inhibitor therapy would be effective in cancer, and we expect that this study will trigger more clinical and preclinical studies examining the crosstalk between TP53 status and chemotherapy.
